Telix Pharmaceuticals Reports the First Patient Dosing in P-III (ZIRCON-CP) Trial of TLX250-CDx for Kidney Cancer Imaging in China
Shots:
- Telix and Grand Pharma have dosed the first patient in China under the P-III (ZIRCON-CP) trial of TLX250-CDx for clear cell renal cell carcinoma at Beijing Cancer Hospital
- The registrational P-III (ZIRCON-CP) trial will involve 82 Chinese patients to assess the diagnostic utility of TLX250-CDx for ccRCC. It is a bridging study to global P-III (ZIRCON; n=300, evaluable: 284) trial, which met all EPs showing 86% sensitivity, 87% specificity & 93% mean positive-predictive value. Data will support future marketing applications
- TLX250-CDx (Zircaix) is a PET imaging agent in studies for the characterization of renal masses as ccRCC or non-ccRCC
Ref: PR Newswire | Image: Telix Pharmaceuticals
Related News:- Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
